Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01986166 · ClinicalTrials.gov registry record · Phase 1
A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS
A Phase 1 study of Neoplasms, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 9
- Study locations
NCT01986166 is a Phase 1 study of Neoplasms that has completed, run by Genentech. The registered enrollment target is 23 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT01986166, a Phase 1 study of Neoplasms, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 9
- Study locations
Study Summary
This open-label, multicenter, global Phase Ib study will evaluate the safety, tolerability and pharmacokinetics of intravenous (IV) dosing of MEHD7945A in combination with oral dosing of cobimetinib in patients with locally advanced or metastatic solid tumors that carry a Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutation and for which standard therapies do not exist, have proven ineffective or intolerable or are considered inappropriate. The study comprises a dose-escalation (Stage 1) and an indication-specific cohort expansion stage (Stage 2).
Conditions Studied
Interventions
- DRUG Cobimetinib
- DRUG MEHD7945A
Study Locations (9)
California
- - San Francisco
Colorado
- - Denver
Connecticut
- - New Haven
Michigan
- - Detroit
Tennessee
- - Nashville
Texas
- - Dallas
Barcelona
- - Barcelona
Madrid
- - Madrid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-11 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01986166
The ClinicalTrials.gov registry entry for NCT01986166 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Cobimetinib is the first listed.
NCT01986166 reports 9 study locations spanning 9 distinct geographic areas - top geographies include California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT01986166 about?
NCT01986166 is a clinical study titled "A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS". This open-label, multicenter, global Phase Ib study will evaluate the safety, tolerability and pharmacokinetics of intravenous (IV) dosing of MEHD7945A in combination with oral dosing of cobimetinib in patients with locally advanced or metastatic solid tumors that carry a Kirsten Rat Sarcoma Viral O...
What is the current status of trial NCT01986166?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2013-11. Estimated completion is 2016-01.
What conditions does trial NCT01986166 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT01986166?
The interventions under investigation include: Cobimetinib (DRUG), MEHD7945A (DRUG).
Who is sponsoring clinical trial NCT01986166?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01986166 being conducted?
This trial has 9 study locations across California, Colorado, Connecticut, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.